• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

慢性肾脏病与非酒精性脂肪性肝病——二者有关联吗?

Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link?

作者信息

Orlić L, Mikolasevic I, Bagic Z, Racki S, Stimac D, Milic S

机构信息

Division of Internal Medicine, Department of Nephrology and Dialysis, University Hospital Center Rijeka, 51000 Rijeka, Croatia.

Division of Internal Medicine, Department of Gastroenterology, University Hospital Center Rijeka, 51000 Rijeka, Croatia.

出版信息

Gastroenterol Res Pract. 2014;2014:847539. doi: 10.1155/2014/847539. Epub 2014 Mar 6.

DOI:10.1155/2014/847539
PMID:24729784
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC3963366/
Abstract

Research in recent years has led to the recognition of the importance of nonalcoholic fatty liver disease (NAFLD) and its relationship to the metabolic syndrome (MS). This has led to a growing interest in the potential prognostic value of NAFLD for adverse cardiovascular disease (CVD) outcome. On the other hand, searching for new risk factors for chronic kidney disease (CKD) development and progression is very important. Growing evidence suggests that the MS is an important factor in the pathogenesis of CKD. The best confirmation of this pathogenic link is hypertensive and diabetic nephropathy as the main causes of CKD. Furthermore, the possible link between NAFLD and CKD has also attracted research interest and recent data suggest an association between these two conditions. These findings have fuelled concerns that NAFLD may be a new and added risk factor for the development and progression of CKD. NAFLD and CKD share some important cardiometabolic risk factors and possible common pathophysiological mechanisms, and both are linked to an increased risk of incident CVD events. Therefore, common factors underlying the pathogenesis of NAFLD and CKD may be insulin resistance, oxidative stress, activation of rennin-angiotensin system, and inappropriate secretion of inflammatory cytokines by steatotic and inflamed liver.

摘要

近年来的研究已使人们认识到非酒精性脂肪性肝病(NAFLD)的重要性及其与代谢综合征(MS)的关系。这引发了人们对NAFLD对不良心血管疾病(CVD)结局潜在预后价值的日益关注。另一方面,寻找慢性肾脏病(CKD)发生和进展的新危险因素非常重要。越来越多的证据表明,MS是CKD发病机制中的一个重要因素。这种致病联系的最佳例证是高血压性和糖尿病性肾病作为CKD的主要病因。此外,NAFLD与CKD之间可能的联系也引起了研究兴趣,最近的数据表明这两种情况之间存在关联。这些发现引发了人们对NAFLD可能是CKD发生和进展的一个新的额外危险因素的担忧。NAFLD和CKD有一些重要的心脏代谢危险因素以及可能的共同病理生理机制,并且两者都与发生CVD事件的风险增加有关。因此,NAFLD和CKD发病机制的共同因素可能是胰岛素抵抗、氧化应激、肾素 - 血管紧张素系统的激活以及脂肪变性和炎症性肝脏不适当分泌炎性细胞因子。

相似文献

1
Chronic kidney disease and nonalcoholic Fatty liver disease-is there a link?慢性肾脏病与非酒精性脂肪性肝病——二者有关联吗?
Gastroenterol Res Pract. 2014;2014:847539. doi: 10.1155/2014/847539. Epub 2014 Mar 6.
2
Risk of chronic kidney disease in patients with non-alcoholic fatty liver disease: is there a link?非酒精性脂肪性肝病患者的慢性肾脏病风险:两者之间是否存在关联?
J Hepatol. 2011 May;54(5):1020-9. doi: 10.1016/j.jhep.2010.11.007. Epub 2010 Nov 17.
3
Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction.非酒精性脂肪性肝病;肾移植受者代谢综合征的一部分及同种异体移植功能障碍的可能原因。
Med Hypotheses. 2014 Jan;82(1):36-9. doi: 10.1016/j.mehy.2013.10.030. Epub 2013 Nov 9.
4
Increased risk of cardiovascular disease and chronic kidney disease in NAFLD.非酒精性脂肪性肝病患者发生心血管疾病和慢性肾脏病的风险增加。
Nat Rev Gastroenterol Hepatol. 2012 May 8;9(7):372-81. doi: 10.1038/nrgastro.2012.79.
5
Nonalcoholic fatty liver disease (NAFLD)--is it a new marker of hyporesponsiveness to recombinant human erythropoietin in patients that are on chronic hemodialysis?非酒精性脂肪性肝病(NAFLD)——它是慢性血液透析患者对重组人促红细胞生成素低反应性的新标志物吗?
Med Hypotheses. 2014 Dec;83(6):798-801. doi: 10.1016/j.mehy.2014.10.012. Epub 2014 Oct 22.
6
Nonalcoholic Fatty Liver Disease and the Kidney: A Review.非酒精性脂肪性肝病与肾脏:综述
Biomedicines. 2021 Oct 1;9(10):1370. doi: 10.3390/biomedicines9101370.
7
Fatty Liver and Chronic Kidney Disease: Novel Mechanistic Insights and Therapeutic Opportunities.脂肪肝与慢性肾脏病:新的发病机制研究与治疗机会
Diabetes Care. 2016 Oct;39(10):1830-45. doi: 10.2337/dc15-1182.
8
Lipid Disorders in NAFLD and Chronic Kidney Disease.非酒精性脂肪性肝病和慢性肾脏病中的脂质紊乱
Biomedicines. 2021 Oct 6;9(10):1405. doi: 10.3390/biomedicines9101405.
9
NAFLD as a driver of chronic kidney disease.非酒精性脂肪性肝病作为慢性肾脏病的一个驱动因素。
J Hepatol. 2020 Apr;72(4):785-801. doi: 10.1016/j.jhep.2020.01.013. Epub 2020 Feb 12.
10
Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.非酒精性脂肪性肝病(NAFLD):透析患者发生不良心血管事件的新危险因素。
Med Hypotheses. 2014 Feb;82(2):205-8. doi: 10.1016/j.mehy.2013.11.039. Epub 2013 Dec 8.

引用本文的文献

1
The Fatty Liver Index's Association with Incident Chronic Kidney Disease in Korean Middle-Aged Adults: A Community-Based Cohort Study.韩国中年成年人中脂肪肝指数与慢性肾脏病发病的关联:一项基于社区的队列研究
J Clin Med. 2024 Mar 12;13(6):1616. doi: 10.3390/jcm13061616.
2
Renal Endocannabinoid Dysregulation in Obesity-Induced Chronic Kidney Disease in Humans.肥胖症相关慢性肾脏病患者肾脏内源性大麻素系统失调。
Int J Mol Sci. 2023 Sep 4;24(17):13636. doi: 10.3390/ijms241713636.
3
Genetically proxied therapeutic prolyl-hydroxylase inhibition and cardiovascular risk.遗传关联的治疗脯氨酰羟化酶抑制与心血管风险。
Hum Mol Genet. 2023 Jan 13;32(3):496-505. doi: 10.1093/hmg/ddac215.
4
Influence of Nonalcoholic Fatty Liver Disease on the Occurrence and Severity of Chronic Kidney Disease.非酒精性脂肪性肝病对慢性肾脏病发生及严重程度的影响
J Clin Transl Hepatol. 2022 Feb 28;10(1):164-173. doi: 10.14218/JCTH.2021.00171. Epub 2021 Sep 22.
5
Retrospective study of factors associated with progression and remission/regression of diabetic kidney disease-hypomagnesemia was associated with progression and elevated serum alanine aminotransferase levels were associated with remission or regression.糖尿病肾病进展及缓解/消退相关因素的回顾性研究——低镁血症与进展相关,而血清丙氨酸氨基转移酶水平升高与缓解或消退相关。
Diabetol Int. 2021 Jan 2;12(3):268-276. doi: 10.1007/s13340-020-00483-1. eCollection 2021 Jul.
6
Unconjugated p-cresol activates macrophage macropinocytosis leading to increased LDL uptake.未结合的对甲酚激活巨噬细胞巨胞饮作用,导致 LDL 摄取增加。
JCI Insight. 2021 Jun 8;6(11):144410. doi: 10.1172/jci.insight.144410.
7
Which factors influence liver stiffness measured by real-time two dimensional shear wave elastography in patients on maintenance hemodialysis?哪些因素会影响维持性血液透析患者通过实时二维剪切波弹性成像测量的肝脏硬度?
Croat Med J. 2021 Feb 28;62(1):34-43. doi: 10.3325/cmj.2021.62.34.
8
Impact of Fasting Lipid Profile on Chronic Kidney Disease Patients Having Fatty Liver Disease.空腹血脂谱对合并脂肪肝疾病的慢性肾脏病患者的影响。
Cureus. 2020 Oct 25;12(10):e11146. doi: 10.7759/cureus.11146.
9
Common Drug Pipelines for the Treatment of Diabetic Nephropathy and Hepatopathy: Can We Kill Two Birds with One Stone?治疗糖尿病肾病和肝病的常见药物研发途径:一石二鸟?
Int J Mol Sci. 2020 Jul 13;21(14):4939. doi: 10.3390/ijms21144939.
10
Circulating fatty acid-binding protein 1 (FABP1) and nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus.循环脂肪酸结合蛋白 1(FABP1)与 2 型糖尿病患者的非酒精性脂肪性肝病。
Int J Med Sci. 2020 Jan 14;17(2):182-190. doi: 10.7150/ijms.40417. eCollection 2020.

本文引用的文献

1
Nonalcoholic fatty liver disease (NAFLD): a new risk factor for adverse cardiovascular events in dialysis patients.非酒精性脂肪性肝病(NAFLD):透析患者发生不良心血管事件的新危险因素。
Med Hypotheses. 2014 Feb;82(2):205-8. doi: 10.1016/j.mehy.2013.11.039. Epub 2013 Dec 8.
2
Non-alcoholic fatty liver disease; a part of the metabolic syndrome in the renal transplant recipient and possible cause of an allograft dysfunction.非酒精性脂肪性肝病;肾移植受者代谢综合征的一部分及同种异体移植功能障碍的可能原因。
Med Hypotheses. 2014 Jan;82(1):36-9. doi: 10.1016/j.mehy.2013.10.030. Epub 2013 Nov 9.
3
Chronic kidney disease and nonalcoholic Fatty liver disease proven by transient elastography.经瞬时弹性成像证实的慢性肾脏病和非酒精性脂肪性肝病。
Kidney Blood Press Res. 2013;37(4-5):305-10. doi: 10.1159/000350158. Epub 2013 Sep 12.
4
Extrahepatic complications of nonalcoholic fatty liver disease.非酒精性脂肪性肝病的肝外并发症。
Hepatology. 2014 Mar;59(3):1174-97. doi: 10.1002/hep.26717. Epub 2014 Jan 16.
5
Relationship between non-alcoholic fatty liver disease and kidney function: a communication between two organs that needs further exploration.非酒精性脂肪性肝病与肾功能之间的关系:两个器官之间的联系尚待进一步探索。
Arab J Gastroenterol. 2012 Dec;13(4):161-5. doi: 10.1016/j.ajg.2012.06.010. Epub 2012 Sep 10.
6
Nonalcoholic fatty liver disease/steatohepatitis: epidemiology, pathogenesis, clinical presentation and treatment.非酒精性脂肪性肝病/肝炎:流行病学、发病机制、临床表现和治疗。
Dig Dis. 2012;30(2):158-62. doi: 10.1159/000336669. Epub 2012 Jun 20.
7
The diagnosis and management of non-alcoholic fatty liver disease: practice Guideline by the American Association for the Study of Liver Diseases, American College of Gastroenterology, and the American Gastroenterological Association.非酒精性脂肪性肝病的诊断与管理:美国肝病研究协会、美国胃肠病学会和美国胃肠病协会实践指南
Hepatology. 2012 Jun;55(6):2005-23. doi: 10.1002/hep.25762.
8
Chronic kidney disease, insulin resistance, and incident diabetes in older adults.老年人慢性肾脏病、胰岛素抵抗与新发糖尿病。
Clin J Am Soc Nephrol. 2012 Apr;7(4):588-94. doi: 10.2215/CJN.11861111. Epub 2012 Mar 1.
9
Metabolic syndrome and insulin resistance as risk factors for development of chronic kidney disease and rapid decline in renal function in elderly.代谢综合征和胰岛素抵抗是老年患者发生慢性肾脏病及肾功能快速下降的危险因素。
J Clin Endocrinol Metab. 2012 Apr;97(4):1268-76. doi: 10.1210/jc.2011-2658. Epub 2012 Feb 15.
10
Metabolic syndrome, insulin resistance and kidney function in non-diabetic individuals.非糖尿病个体中的代谢综合征、胰岛素抵抗与肾功能。
Nephrol Dial Transplant. 2012 Apr;27(4):1410-5. doi: 10.1093/ndt/gfr498. Epub 2011 Sep 8.